NCT05370521Phase 2Terminated

A Study of Safety and Efficacy of Tildacerfont in Females With Polycystic Ovary Syndrome and Elevated Adrenal Androgens

Study sponsor: Spruce Biosciences

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2023-08-03Actual
Enrollment · participants27Actual
Source updated2025-10-09Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview